Business Context and Reporting Period
Company: Arrowhead Research Corporation (a development-stage nanotechnology holding company).
Filing Type: Form 10-Q (Quarterly Report).
Period Ended: March 31, 2010.
Business Model: The Company forms, acquires, and operates subsidiaries commercializing nanotechnologies in electronics and biotech. Key subsidiaries include Unidym (carbon nanotubes) and Calando Pharmaceuticals (oncology drug delivery). The Company also holds minority investments in Nanotope and Leonardo Biosystems.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2010 |
Six Months Ended Mar 31, 2010 |
|---|---|---|
| Revenue | $157,346 | $305,414 |
| Net Loss (Attributable to Arrowhead) | $(1,853,960) | $(3,398,887) |
| Operating Loss | $(2,129,459) | $(4,289,677) |
| Cash and Cash Equivalents | $2,593,044 | $2,593,044 (Ending Balance) |
| Total Assets | $7,758,203 | $7,758,203 (Ending Balance) |
| Total Liabilities | $2,279,634 | $2,279,634 (Ending Balance) |
| Stockholders' Equity | $5,478,569 | $5,478,569 (Ending Balance) |
| Net Cash Used in Operating Activities | N/A | $(3,393,020) |
Note: The filing does not provide explicit margin percentages due to the development-stage nature of the business and significant operating losses.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased to $157,346 for the quarter ended March 31, 2010, from $235,650 in the same period in 2009. This is primarily due to the depletion of carbon nanotube inventories at Unidym and the cessation of grant revenue.
- Reduced Losses: Net loss attributable to Arrowhead improved significantly to $(1.85) million for the quarter, compared to $(5.29) million in the prior year quarter. This improvement is driven by aggressive cost-cutting measures, including workforce reductions and facility closures at Unidym and Calando.
- Expense Reductions:
- Salaries: Decreased by 57% year-over-year for the quarter.
- R&D Expenses: Decreased by 77% year-over-year for the quarter, largely due to the closure of Unidym's Texas facility and Calando's lab.
- G&A Expenses: Decreased by 28% year-over-year for the quarter.
- Discontinued Operations: The Company recorded a gain of $414,796 from discontinued operations for the six months ended March 31, 2010, primarily resulting from the sale of Tego Biosciences' intellectual property assets to Luna Innovations, Inc.
Outlook, Risks, and Management Commentary
- Liquidity and Capital Resources: As of March 31, 2010, the Company held approximately $2.6 million in cash. Management estimates this is sufficient to fund operations through September 30, 2010, assuming no additional financing. The Company anticipates needing further equity financings, asset sales, or license agreements to continue operations beyond this date.
- Strategic Shift: The Company has adopted a cash conservation strategy. Unidym is focusing on licensing and partnering for manufacturing rather than internal production. Calando has closed its lab and is seeking partners for its drug delivery platform (CALAA-01) rather than funding internal clinical trials.
- Key Risks:
- Insolvency Risk: Unidym's license from Rice University includes an insolvency provision; failure to meet financial covenants could result in the loss of critical intellectual property.
- Debt Obligations: Unidym has a capital lease obligation of $296,419 due in four monthly installments. Calando has a $500,000 convertible note maturing in November 2010.
- Market Acceptance: Commercialization of nanotechnology products remains uncertain and dependent on third-party partnerships.
- NASDAQ Compliance: The Company regained compliance with NASDAQ listing rules in April 2010 after a previous deficiency notice regarding stock price.
Investor Verification Checklist
- Cash Runway: Verify if the Company has secured additional financing to extend operations beyond the projected September 30, 2010 date.
- Debt Service: Confirm Unidym's ability to meet the $75,000 monthly capital lease payments and Calando's ability to refinance or repay the $500,000 note due in late 2010.
- Partnership Progress: Monitor announcements regarding licensing deals for Calando's CALAA-01 and Unidym's transparent conductive films, as these are critical for future revenue.
- Intellectual Property Status: Review Unidym's compliance with the Rice University license solvency covenants to ensure no risk of IP termination.
- Stock Dilution: Assess the impact of outstanding warrants (approx. 19.7 million) and options on future equity dilution if financing is required.